您要查找的是不是：
- Selective Elimination of Alloreactive Donor Lymphocytes by Using TBI and Cyclophosphamide TBI和环磷酰胺选择性去除同种异基因反应供者淋巴细胞的研究
- Experimental study on prevention of graft-versus-host disease by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation 移植前选择性去除同种异体反应供者淋巴细胞预防移植物抗宿主病的实验研究
- alloreactive donor lymphocytes 同种异体反应供者淋巴细胞
- alloreactive donor lymphocyte 同种异基因反应供者淋巴细胞
- GVHD is the result of the immune attack by donor lymphocytes (the graft) against the recipient’s tissues (the host). GVHD是供体淋巴细胞（移植物）免疫攻击接受者的组织（宿主）的结果。
- Conclusion The selective depletion of alloreactive donor T cells based on expression of two activation-induced antigens CD25(superscript +) and CD69(superscript +) can coordinate GVHD and GVT. 结论体外选择性去除表达以CD25(上标+)、CD69(上标+)的同种异体反应T细胞可以协调移植物抗宿主病和移植物抗肿瘤。
- The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. 对于在移植后出现淋巴瘤的免疫抑制患者，使用供者的淋巴细胞来进行ACT是一种有效的治疗手段。
- Methods First,the serosal effusion was drained thoroughly,then donor lymphocytes were injected into pleural cavity once for all. 方法首先最大限度地排净浆膜腔积液,然后将采集的供体淋巴细胞经穿刺直接注入浆膜腔内。
- GVHD can also be a factor in donor lymphocyte infusion. 此外，GVHD也是供体淋巴细胞输注的一个因素。
- Objective:To study engraftment kinetic for directing donor lymphocyte infusion (DLI). 目的 :观察移植物动力学变化 ,指导供者淋巴细胞输注 (DL I)。
- Five patients with malignant hematonosis were received donor lymphocyte infusion(DLI) after transplantation. 对5例恶性血液病实施供者淋巴细胞输注。
- Mixed chimerism (MC) patients in group C were subjected to donor lymphocyte infusion (DLI). C组形成混合性嵌合体后行供者淋巴细胞输注(DLI)。
- A potential risk of donor lymphocyte infusion is severe graft versus host disease (GVHD). 供体淋巴细胞输注的一个潜在风险是严重的移植物抗宿主病（GVHD）。
- Methods:The clinical data of 12 cases undergoing allo-HSCT and 4 cases with donor lymphocyte infusion(DLI) were analyzed. 方法:总结12例血液病患者经allo-HSCT及4例供者淋巴细胞输注(DLI)治疗的临床资料。
- Keywords Malignant serosal effusion;Donor lymphocytes; 淋巴细胞注射;恶性浆膜腔积液;
- Objective To evaluate the application of donor lymphocyte infusion (DLI) after nonmyeloablative stem cell transplantation (NSCT) for hematologic malignancies. 目的探讨供者淋巴细胞输注(DLI)治疗非清髓性异基因造血干细胞移植后血液病复发的疗效。
- To explore clinical curative effect of donor lymphocyte infusion followed by non-myeloablative haemotopoietic stem cell transplantation for acute leukemia. 探讨非清髓性造血干细胞移植后供者淋巴细胞输注治疗急性白血病的疗效。
- Objective To explore clinical curative effect of donor lymphocyte infusion followed by non-myeloablative haemotopoietic stem cell transplantation for acute leukemia. 目的探讨非清髓性造血干细胞移植后供者淋巴细胞输注治疗急性白血病的疗效。
- Objective To explore the graft versus leukemia effects of donor lymphocyte infusion(DLI) after nonmyeloablative allogeneic bone marrow transplantation while attenuating treatment associated morbidity, mortality and graft versus host disease. 目的 探讨非清除性异基因骨髓移植 (allo BMT)后供者淋巴细胞输注 (DLI)是否能减少移植相关并发症、相关死亡和减轻移植物抗宿主病 (GVHD) ,是否能增强移植物抗白血病 (GVL)效应。
- Four patients experienced no acute graft-versus-host disease (GVHD) at all,one (case 1) of whom subsequently had chronic GVHD in skin after the fifth donor lymphocyte infusion (DLI) and another (case 3) had chronic GVHD after the seventh DLI. 4例均未发生急性移植物抗宿主病 ,例 1于第 5次供者淋巴细胞输注后发生皮肤慢性移植物抗宿主病 ,例 3于第 7次供者淋巴细胞输注后发生慢性移植物抗宿主病。
